The Impact of Alternative Payment Models on Oncology Innovation and Patient Care.

Oncology care is in a time of major transformation. Scientific discovery is driving breakthroughs in prevention, diagnostics, and treatment, resulting in tremendous gains for patients as the number of cancer survivors continues to grow on an annual basis. At the same time, there is mounting pressure across the healthcare system to contain costs while improving the quality of cancer care.

Accelerating the delivery of patient-centered, high-quality cancer care.

Significant progress has been made in the past 50 years across the field of oncology, and, as a result, the number of cancer survivors in the United States is more than 14.5 million. In fact, the number of cancer survivors continues to grow on an annual basis, which is due in part to improved treatments that help people with cancer live longer, and improvements in early detection that allow doctors to find cancer earlier when the disease is easier to treat.

How molecular medicine transforms policy (and everything else).

Molecular medicine (also known as pharmacogenomics, pharmacogenetics, gene-based medicine, personalized medicine), after being heralded prematurely as the next revolution in medicine, is in the process now of becoming the first big change in healthcare of the 21st century. Because its scientific, clinical, ethical, financial, and regulatory implications are so far-reaching, it is important to define who and what will be affected in order to put the right societal systems and policies in place to cope with the change. Leaders of the personalized medicine field will be those organizations that see the wave and prepare to adjust their traditional planning, relationships, attitudes and management approach.